Expression of transcription factor Pokemon in non-small cell lung cancer and its clinical significance

Chinese Medical Journal

Volumn 121, Issue 5, 2008, Pages 445-449

  Zhao, Zhi Hong ^a   Wang, Sheng Fa ^a   Yu, Liang ^a   Wang, Ju ^a   Chang, Hao ^a   Yan, Wei Li ^a   Fu, Kai ^a   Zhang, Jian ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Lung cancer; Pokemon; Prognosis

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR POKEMON; UNCLASSIFIED DRUG; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; SURVIVAL RATE; WESTERN BLOTTING; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 42449125221     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200803010-00015     Document Type: Article

References (21)

1. Maeda T, Hobbs RM, Pandolfi PP. The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer Res 2005, 65: 8575-8578.
2. Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 2005, 433: 278-285.
3. Rovin RA, Winn R. Pokemon expression in malignant glioma: an application of bioinformatics methods. Neurosurg Focus 2005; 19: E8.
4. Cui M, Xu H, Yang Y. Expression and clinical significance of Pokemon protein in breast cancer. J Clin Surg (Chin) 2007, 15: 399-401.
5. Ji Y, He XS, Ma Y, Zhu XF, Zhang R, On ZH. Expression of Pokemon in hepatocellular carcinoma tissue, adjacent and far tissue, hepatocirrhosis and normal liver tissue. Chin J Exp Surg (Chin) 2007; 24: 187-189.
6. Apostolopoulou K, Pateras IS, Evangelou K, Tsantoulis IK, Liontos M, Kittass C, et al. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. J Pathol 2007; 213: 294-302.
7. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-1812.
8. Liu CJ, Prazak L, Fajardo M, Yu S, Tyagi N, Di Cesare PE. Leukemia/ lymphomarelated factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibits cartilage oligomeric matrix protein gene expression and chondrogenesis. J Biol Chem 2004; 279: 47081-47091.
9. Schubot FD, Tropea JE, Waugh DS. Structure of the POZ domain of human LRE, a master regulator of oncogenesis. Biochem Biophys Res Commun 2006;351: 1-6.
10. Costoya JA. Functional analysis of the role of POK transcription repressors Brief Funet Genomic Proteomic 2007; 6: 848.
11. Melnick A. Carlile G, Ahmad KF, Kiang CL, Corcoran C. Bardwell V, et al. Critical residues within the BTB domain of PLZF and Bel-6 modulate interaction with corepressors. Mol Cell Biol 2002; 22: 1804-1818.
12. Costoya JA, Hobbs RM, Barna M, Cattoretti G, Manova K, Sukhwani M, et al. Essential role of Plzf in maintenance of sperma- togonial stem cells. Nat Genet 2004, 36: 653-659.
13. He X, Dave VP, Zhang Y, Hua X, Nicolas E, Xu W, et al. The zinc finger transcription tactor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature 2005; 433: 826-833.
14. Roh HE, Lee MN, Jeon BN, Choi WI, Kim YJ, Yu MY, et al. Regulation of Pokemon 1 activity by sumoylation. Cell Physiol Biochem 2007; 20: 167-180.
15. Davies JM, Hawe N, Kabarowski J, Huang QH, Zhu J, Brand NJ, et al. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene. Oncogene 1999, 18: 365-375.
16. Tang S, Luo H, Yu J, Yang D, Shu J. Relationship between alterations of p161NK4a and p14ARF gene of CDKN2A locus and gastric carcinogenesis. Chin Med J 2003; 116: 1083-1087.
17. Zhang QH, Ni QX, Gan J, Shen ZZ, Luo JM, Jin C, et al. p14ARF upregulation of p53 and enhanced effects of 5-fluorouracil in pancreatic cancer. Chin Med J 2003, 116: 1150-1155.
18. Kim WY, Sharpless NE. The regulation of INK/ARF in cancer and aging. Cell 2006; 127: 265-275.
19. Nicholson SA, Okby NT, Khan MA, Welsh JJA, Memenamin MG, Travis WD, et al. Alterations a p14ARF, pA, and Q genes involved in the E2F-1-mcdiatcd apoptotic pathways in non-small cell lung carcinoma. Cancer Res 2001; 61: 5636-5643.
20. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exchusive events in primay human lung tumors. Oncogene 2002; 21: 2750-2761.
21. Hsu HS, Wang YC, Tseng RC, Chang JW, Chen JT. Shih CM, et al. 5'cytosine-phosphoguanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer. Clin Cancer Res 2004, 10: 4734-4741.